Mitokinin
  • Our Science
    • PINK1
    • Therapeutic Approach
  • About Us
  • News
  • Contact
  • Menu

News

March 2, 2021

Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie

Agreement focused on advancing Mitokinin’s PINK1 activator program for the potential treatment of Parkinson’s disease

Learn more

February 7, 2020

Mitokinin CSO Nicholas Hertz, PhD, to present at February 2020 Keystone Symposium

Mitokinin CSO Nicholas Hertz, PhD, will be presenting an overview of the Company’s PINK1 program…

Learn more

January 12, 2020

Mitokinin Presents at 3rd Annual Sachs Neuroscience Investor Forum

Mitokinin joined 300 delegates from the biopharma and venture industries and 35 peer companies at the 3rd annual Sachs Neuroscience Investor Forum…

Learn more

October 15, 2019

Mitokinin announces new award from the Michael J. Fox Foundation

Mitokinin today announced that The Michael J. Fox Foundation has awarded the Company a $300,000 grant to advance…

Learn more

October 1, 2019

Mitokinin appoints Michael D. Taylor, PhD, Executive Chairman

Mitokinin, a late-preclinical stage biotechnology company developing PINK1-targeted therapies for…

Learn more

June 15, 2019

Mitokinin to present at the Keystone Symposium on Neurodegeneration

Mitokinin, a late-preclinical stage biotechnology company developing PINK1-targeted therapies for…

Learn more

Copyright © 2021 Mitokinin. All rights reserved.

Website designed and developed by RainCastle Communications, Inc.

Scroll to top